Through a statement, The Federal Commission for the Protection against Health Risks (Cofepris) warns about the illegal marketing of Combovir (nirmatrelvir 150 mg / ritonavir 100 mg) tablets, manufactured by Bruck Pharma Private Limited, for the treatment of COVID-19.
Cofepris detected the sale of the drug on digital platforms. As it does not have a health registration in Mexico, its composition, purity, safety, efficacy or quality cannot be guaranteed.
Furthermore, the manufacturing, storage and transportation conditions are unknown, which represents a health risk.
The health agency recommends to the population Do not purchase Combovir (nirmatrelvir 150 mg/ritonavir 100 mg) tablets with any lot number and expiration date.
LEE: Media Alliance condemns attack against El Debate newspaper
COFEPRIS
Likewise, Cofepris urges not to acquire or consume products that do not have health record or that are labeled in languages other than Spanish.
It also recommends not purchasing medications through social networks, sales platforms and other online sites, mainly those that are offered at a lower price than the market, and those that require assessment, prescription and medical supervision, such as those that are intended to treat COVID-19.
You may be interested in: Volaris: What is the difference between personal belongings, carry-on and checked luggage?
If you have used the medication and present any symptoms, adverse reactions or discomfort, the population is invited to report it to the following online link.
*Stay up to date with the news, join our WhatsApp channel here: https://whatsapp.com/channel/0029VaAf9Pu9hXF1EJ561i03
MV
